MedTrace Logo

Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate

NCT02532842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2015-11-03

No results posted yet for this study

Summary

The primary objective of this study is to explore hospitalization (number, length and reasons for psychiatric hospitalizations) in young, adult, newly diagnosed schizophrenia participants during the first 12 months of treatment with once monthly paliperidone palmitate in naturalistic clinical settings.

Conditions

Sponsors & Collaborators

  • Janssen Pharmaceutica N.V., Belgium

    lead INDUSTRY

Principal Investigators

  • Clinical Trial Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium

Eligibility

Min Age
18 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Croatia
  • Russia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02532842 on ClinicalTrials.gov